The Human Genome: Yours for $48,000
The cost of a personal genome has dropped from about the price of a luxury sedan to, well, the price of a slightly less luxurious nice car. Illumina, a genomics technology company headquartered in San Diego, announced the launch of a $48,000 genome-sequencing service at the Consumer Genetics Conference in Boston on Wednesday.
It won’t be the first consumer genome service–Knome, a startup in Cambridge, MA, already offers genome sequencing for just under $100,000–but Illumina is the first company preparing to offer high-volume personal-genome sequencing. Knome, which uses Illumina technology to perform its sequencing, is a boutique service that offers both genome analysis and interpretation.
Many within the genomics industry believe that, as soon as the price is right, an individual’s genome will be sequenced routinely and become part of her medical record. Within the genome lie clues to each person’s risk for disease, his or her reaction to different medications, and other medically useful information.
While $48,000 is still out of reach for most consumers, the price reflects an exponential drop in the cost of sequencing technologies in recent years. James Watson’s genome, sequenced in 2007, cost about $2 million, and Knome initially offered its service at $350,000. A third company, Complete Genomics, announced plans for a $5,000 sequencing service, although this will initially be available only to academic institutions and industry for research and clinical trials rather than for personal use. “It’s like watching the price of gas fall,” says George Church, a genomics technologist at Harvard University who has developed his own sequencing technology.
Unlike most consumer-genomics companies, which offer tests directly through the Internet, Illumina’s genome-sequencing service will require a physician’s prescription. In fact, the company will implement a seven-day waiting period after an individual surrenders his saliva for analysis to give customers time to make sure that they truly want to know the contents of their genome.
The $48,000 price tag comes with 30-fold coverage of the entire genome (an individual’s DNA must be analyzed multiple times to generate a comprehensive sequence) but minimal analysis of the information that it holds. Instead, Illumina will leave the analysis to others, announcing partnerships with four major consumer-genomics companies: Knome, 23andMe, Navigenics, and Decode. Jay Flatley, Illumina’s chief executive officer, said at the Consumer Genetics Conference that each company will develop its own analysis packages at an additional cost, and consumers will be able to pick the one that they want.
It’s the analysis of the genome rather than the sequencing itself that is proving to be the most difficult aspect of personalized genomic medicine. While scientists have identified hundreds of genetic variations linked to risk of specific diseases, the meaning of the vast majority of the genome is still unknown. And in most cases, scientists don’t yet know how to combine genetic risk factors with environmental risk factors to produce accurate predictions for the likelihood of developing a specific disease.
Currently, 23andMe, Navigenics, and Decode use gene chips to analyze specific genetic variations commonly found in different populations that have been linked to diseases and other traits. Whole-genome sequencing captures a much higher volume of genetic information, as well as additional types of genetic variation, such as deletions and duplications of segments of the genome. Knome already provides analysis of the entire genome and thus will likely have a leg up on the competition in terms of interpretation. Jorge Conde, Knome’s president, says that the company will still offer its $99,000 service, which includes in-person interpretation by a panel of experts. In contrast, Knome’s service, provided through Illumina, would be automated.
Flatley has already had his genome sequenced and has announced three others currently being analyzed: Hermann Hauser, a venture capitalist with Amadeus Capital Partners who was involved with Solexa, the startup on which Illumina’s sequencing technology is based; Henry Louis Gates Jr., a Harvard professor who has used genomics to explore African-American history; and Gates’s father, Henry Gates Sr.
Illumina is also developing an application for the iPhone that would allow consumers to interact with their genetic information in different ways. One example is a feature that determines which statin medication an individual should take, as well as the optimal dose, based on her genome.
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Deep learning pioneer Geoffrey Hinton has quit Google
Hinton will be speaking at EmTech Digital on Wednesday.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.